12/2
09:00 am
ydes
YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection
High
Report
YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection
11/24
09:00 am
ydes
YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics
Medium
Report
YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics
11/5
08:30 am
ydes
YD Bio and EG BioMed Expand U.S. Access to OkaiDx™, a cfDNA-Methylation Blood Test for Post-Treatment Breast Cancer Monitoring
Medium
Report
YD Bio and EG BioMed Expand U.S. Access to OkaiDx™, a cfDNA-Methylation Blood Test for Post-Treatment Breast Cancer Monitoring
10/20
10:20 am
ydes
YD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDES
Medium
Report
YD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDES
10/10
08:37 am
ydes
YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities
Medium
Report
YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities
9/30
10:15 pm
ydes
YD Bio Limited Reports Unaudited Half Year 2025 Financial Results [Yahoo! Finance]
High
Report
YD Bio Limited Reports Unaudited Half Year 2025 Financial Results [Yahoo! Finance]
9/30
05:25 pm
ydes
YD Bio Limited Reports Unaudited Half Year 2025 Financial Results
High
Report
YD Bio Limited Reports Unaudited Half Year 2025 Financial Results